orbofiban has been researched along with lamifiban in 2 studies
| Studies (orbofiban) | Trials (orbofiban) | Recent Studies (post-2010) (orbofiban) | Studies (lamifiban) | Trials (lamifiban) | Recent Studies (post-2010) (lamifiban) |
|---|---|---|---|---|---|
| 48 | 17 | 0 | 84 | 12 | 2 |
| Protein | Taxonomy | orbofiban (IC50) | lamifiban (IC50) |
|---|---|---|---|
| Integrin beta-3 | Homo sapiens (human) | 0.0157 | |
| Integrin alpha-IIb | Homo sapiens (human) | 0.0157 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gretler, DD; Scarborough, RM | 1 |
| Jang, IK; Sabatine, MS | 1 |
2 review(s) available for orbofiban and lamifiban
| Article | Year |
|---|---|
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Drug Design; Fibrinolytic Agents; Humans; Injections; Integrins; Molecular Mimicry; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Snake Venoms | 2000 |
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine | 2000 |